Nanion Introduces NPC-Certified Cell Lines
anion now introduces “Nanion Approved Cells”, where commercially available cell lines from several providers have been evaluated and certified based on cell and platform performance for automated patch clamp applications.
Munich (I-Newswire) November 8, 2012 - Nanion Introduces NPC-Certified Cell Lines
Nanion’s automated patch clamp platforms are known for their high cell compatibility, even for primary cells and stem cells. Nanion now introduces “Nanion Approved Cells”, where commercially available cell lines from several providers have been evaluated and certified based on cell and platform performance. The approved cells can be directly purchased through Nanion, so that Nanion’s customers get a complete package of APC platform and validated assay.
A large number of cell lines from several providers, including Millipore and CreaCell have been validated on Nanion’s three automated patch clamp platforms, the Port-a-Patch, Patchliner, and the SyncroPatch 96. Parameters such as average seal-resistance, access resistance, cell recording longevity, ion channel expression and success rates for completed recordings were investigated and documented in a standardized way. Success rates for completed recordings were typically above 70%. With Nanion Approved Cells, the user can rest assured that the assay will run optimally, with minimal or no assay development required.
Atsushi Ohtsuki, Customer Support Manager, Nanion Technologies, Japan says: "The Nanion Approved Cells will be much appreciated by Japanese customers, since the optimization work already has been done by Nanion Technologies, which saves time and reduces the risk of an investment. Additionally, it is also a guarantee, that the customers will encounter minimal problems when starting a new assay on Nanion's automated patch clamp platforms."
Dr. Niels Fertig, CEO of Nanion, continues:
"The certification of commercially available cell lines makes it easier for existing and new customers to invest in new cell lines and our platforms without having to worry about lengthy assay development. It is a well-known fact that Nanion's platforms show great compatibility with a broad range of cells and ion channels, which also is confirmed by the long list of Nanion Approved Cells and scientific publications in high impact journals such as Nature or PNAS. Nanion also certifies cell lines on-demand, meaning that if a customer has a particular cell line of interest, we evaluate and document the cell performance on our platforms, free of charge."
About Nanion Approved Cells
Nanion Approved Cells are commercially available cells, certified on Nanion's three automated patch clamp platforms. Cell and platforms performance as well as ion channel current expression is thoroughly investigated and summarized in a data sheet. The approved cells can be directly purchased from Nanion, so that Nanion's customers get a package of APC platform and validated assay. Nanion also does cell line certification on-demand, if the cell line of interest cannot be found in the list of approved cells. The full list of tested cell lines can be found on Nanion's website: http://www.nanion.de/downloads/npc-certified-cells.html
About Nanion Technologies:
Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established three highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery. Nanion's instruments use planar patch clamp chips which replace the traditional glass pipette used in the technique of patch clamping. Nanion was nominated in 2007 for Germany's most prestigious innovation award the Deutscher Zukunftspreis (German Future Prize, Federal President's Award for Technology and Innovation).
About Nanion Technologies
Nanion Technologies GmbH is a German, privately held, limited company, founded in 2002 as a spin-off More.. from the Center for Nanoscience (CeNS) of the University of Munich, Germany. Nanion’s team has developed and globally established three successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery.
Nanion's high quality instruments employ planar patch clamp chips which replace the traditional glass pipette used in the conventional patch clamp technique. In 2009 Nanion was awarded the German Founders Award (Gründerpreis), and the Innovation Prize Step Award. In 2012, Nanion celebrates its 10th anniversary. Nanion has two subsidiaries: Nanion Technologies Inc., North Brunswick, NJ, USA, opened in 2009, and Nanion Technologies China, opened in 2011.Less..
Phone : +49 89 218997973
Published in:Science and Research
Published On:November 8, 2012
Print Release:Print Release
If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.
F1000Research Aims to Reduce Publication Bias
Phare Consulting Pushes For Comprehensive Growth In the Security Manufacturing Sector
Differentiated & Focused Conference On Polymeric Materials In Medical Devices Undefined. San Francisco, CA, USA, JUNE 26-28, 2013
Capital Resource Partners Purchases Gamma Medica’s Pre-Clinical Business to Form New Entity, Trifoil Imaging
Well Intervention Market Worth $17.48 Billion By 2018